Article

Contrast performance best with zero spherical aberrations

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

By using adaptive optics and physiological eye models, Pablo Artal and colleagues from Universidad de Murcia, Spain have determined that contrast performance peaks when spherical aberration is completely corrected.

An adaptive-optics based vision simulator that allowed for simultaneous manipulation of ocular wavefront aberration and measurement of visual performance was created. The simulator consisted of a wavefront sensor, an adaptive optics mirror and a visual testing path. Subjective measurements of contrast sensitivity in five subjects with different levels of naturally occurring spherical aberration, at 15 c/deg with a 4.8 mm pupil, were performed.

Contrast sensitivity was measured for spherical aberration values of -0.09, 0.0, 0.09 and 0.182 µm with the other naturally occurring aberrations of the eye present and corrected and with defocus varying from +0.5 to -0.5 D. The same levels of spherical aberration were compared in physiological eye models to establish tolerances to tilt and decentration and to verify through-focus performance.

Each subject experienced peak contrast sensitivity performance with varying levels of spherical aberration when their natural aberrations were present, however, the average contrast performance peaked with 0 µm of spherical aberration.

The researchers concluded that contrast performance is at its best when spherical aberration is completely corrected.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.